Purpose Of Review: This review explores the intersection of Mpox and HIV, highlighting clinical manifestations, immune evasion mechanisms, epidemiological challenges, and prevention strategies. People with HIV (PWH), particularly those with low CD4+ cell count, face severe Mpox outcomes. Prevention relies on education, vaccination, and early detection. Integrating Mpox management into HIV care systems is vital.
Recent Findings: Since May 2022, Mpox caused by Orthopoxvirus monkeypox (MPV) Clade IIb, has affected 126 countries. In 2024, Clade Ib emerged in the Democratic Republic of Congo, leading to its declaration as a Public Health Emergency of International Concern (PHEIC). Research on MPV-HIV co-infections has provided genomic insights and protective strategies for PWH. Antivirals like tecovirimat show promise despite emerging resistance concerns.
Summary: The global Mpox outbreak caused by Clade IIb and the emergence of Clade Ib underscores its growing threat. Mpox disproportionately impacts PWH, leading to severe outcomes and higher fatality rates. This review emphasizes clinical challenges, genomic advances, and prevention strategies. Enhanced surveillance, vaccination, and tailored therapies are essential to addressing this evolving health crisis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/COH.0000000000000922 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Prevention and Treatment, Hunan Institute for Tuberculosis Control (Hunan Chest Hospital), Changsha 410013, China.
Objectives: Reducing mortality during anti-tuberculosis treatment is crucial for completing full-course standardized therapy and achieving tuberculosis cure. The study aims to analyze the mortality and its influencing factors among pulmonary tuberculosis patients undergoing anti-tuberculosis treatment in Hunan Province.
Methods: In this retrospective cohort study, data on pulmonary tuberculosis patients from the Hunan Provincial Tuberculosis Management Information System were collected between January 1, 2019 and December 31, 2023.
BMJ Open
March 2025
University of Southern California Keck School of Medicine, Los Angeles, California, USA
Objectives: Extended life expectancy due to treatment improvements has increased the diagnosis of cancer among people living with HIV (PLWH) in Africa. Despite documented impacts of stigma on cancer preventive behaviours and care, little is known about the intersections of cancer and HIV stigma and the effects on prevention and care behaviours for both conditions. This study aims to examine experiences and drivers of cancer stigma and their associations with access to and utilisation of cancer prevention services among PLWH.
View Article and Find Full Text PDFAIDS Care
March 2025
Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil.
In Brazil, pre-exposure prophylaxis (PrEP) is freely available to individuals at high risk of HIV infection. However, knowledge and perception of PrEP can act as barriers to its access and use. This study evaluated PrEP knowledge and perception among healthcare workers in the Unified Health System in a Brazilian capital.
View Article and Find Full Text PDFJMIR Form Res
March 2025
Department of Health Promotion and Disease Prevention, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL, United States.
Background: Online research studies enable engagement with more Black cisgender women in health-related research. However, fraudulent data collection responses in online studies raise important concerns about data integrity, particularly when incentives are involved.
Objective: The purpose of this study was to assess the strengths and limitations of fraud deterrence and detection procedures implemented in an incentivized, cross-sectional, online study about HIV prevention and sexual health with Black cisgender women living in Texas.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!